SLC7A10

Summary

SLC7A10 (solute carrier family 7 member 10, HGNC:11058) is a protein-coding gene on chromosome 19q13.11, encoding Asc-type amino acid transporter 1 (Q9NS82). Associates with SLC3A2/4F2hc to form a functional heterodimeric complex that translocates small neutral L- and D-amino acids across the plasma membrane.

SLC7A10, in association with 4F2HC (SLC3A2; MIM 158070), mediates high-affinity transport of D-serine and several other neutral amino acids (Nakauchi et al., 2000 [PubMed 10863037]).

Source: NCBI Gene 56301 — RefSeq curated summary.

At a glance

• GWAS associations: 23
• Clinical variants (ClinVar): 114 total
• MANE Select transcript: NM_019849

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11058
Approved symbol	SLC7A10
Name	solute carrier family 7 member 10
Location	19q13.11
Locus type	gene with protein product
Status	Approved
Aliases	asc-1
Ensembl gene	ENSG00000130876
Ensembl biotype	protein_coding
OMIM	607959
Entrez	56301

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 nonsense_mediated_decay, 2 protein_coding, 1 retained_intron

ENST00000253188, ENST00000587064, ENST00000590036, ENST00000590490, ENST00000592596, ENST00000936958

RefSeq mRNA: 1 — MANE Select: NM_019849 NM_019849

CCDS: CCDS12431

Canonical transcript exons

ENST00000253188 — 11 exons

Exon	Start	End
ENSE00000695910	33215769	33215973
ENSE00000695925	33211225	33211328
ENSE00000695927	33210802	33210898
ENSE00001301084	33225553	33225850
ENSE00001328575	33208664	33209021
ENSE00001793096	33211414	33211537
ENSE00003505401	33212514	33212639
ENSE00003550499	33210467	33210616
ENSE00003555578	33209308	33209485
ENSE00003614528	33212851	33213002
ENSE00003692026	33212292	33212445

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 88.83.

FANTOM5 (CAGE): breadth broad, TPM avg 1.2651 / max 163.8322, expressed in 252 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180408	1.1069	239
180409	0.0878	36
180407	0.0704	33

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
omental fat pad	UBERON:0010414	88.83	gold quality
peritoneum	UBERON:0002358	88.76	gold quality
adipose tissue of abdominal region	UBERON:0007808	88.39	gold quality
caudate nucleus	UBERON:0001873	85.92	gold quality
nucleus accumbens	UBERON:0001882	84.78	gold quality
adipose tissue	UBERON:0001013	83.97	gold quality
putamen	UBERON:0001874	83.79	gold quality
amygdala	UBERON:0001876	83.08	gold quality
connective tissue	UBERON:0002384	81.81	gold quality
subcutaneous adipose tissue	UBERON:0002190	81.28	gold quality
right frontal lobe	UBERON:0002810	80.40	gold quality
anterior cingulate cortex	UBERON:0009835	79.90	gold quality
cingulate cortex	UBERON:0003027	79.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.99	gold quality
hypothalamus	UBERON:0001898	77.08	gold quality
substantia nigra	UBERON:0002038	76.18	gold quality
telencephalon	UBERON:0001893	76.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.48	gold quality
midbrain	UBERON:0001891	75.18	gold quality
temporal lobe	UBERON:0001871	75.03	gold quality
Brodmann (1909) area 9	UBERON:0013540	75.03	gold quality
neocortex	UBERON:0001950	74.74	gold quality
prefrontal cortex	UBERON:0000451	74.61	gold quality
frontal cortex	UBERON:0001870	74.61	gold quality
ganglionic eminence	UBERON:0004023	74.46	gold quality
cerebral cortex	UBERON:0000956	73.25	gold quality
Ammon’s horn	UBERON:0001954	72.76	gold quality
forebrain	UBERON:0001890	72.65	gold quality
brain	UBERON:0000955	71.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

25 targeting SLC7A10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4639-5P	99.81	67.37	1028
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-1245B-5P	98.88	66.55	576
HSA-MIR-3142	98.88	66.09	529
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-3158-3P	98.45	64.25	560
HSA-MIR-6779-3P	97.51	65.82	789
HSA-MIR-1306-5P	97.11	64.04	755
HSA-MIR-3194-5P	96.80	64.90	1027
HSA-MIR-1295B-3P	96.68	66.11	276
HSA-MIR-2909	96.36	67.30	562

Literature-anchored findings (GeneRIF, showing 10)

• The lack of expression of asc-1 in the proximal tubule indicates that it plays no role in the bulk of renal reabsorption of amino acids (PMID:15458438)
• In conclusion, SLC7A10 had no apparent degree of association with schizophrenia as a candidate susceptibility gene in the disease per se. (PMID:21888942)
• The amino acid transporter ASC-1 is a white adipocyte-specific cell surface protein. (PMID:25080478)
• ASC1 is a target for ufmylation and that UFBP1 is an essential component for ASC1 ufmylation. (PMID:25219498)
• results identify ASC-1 as a novel cell cycle regulator with a key role in cell proliferation. (PMID:31794073)
• Asc-1 Transporter (SLC7A10): Homology Models And Molecular Dynamics Insights Into The First Steps Of The Transport Mechanism. (PMID:32111919)
• NLRC4, ASC and Caspase-1 Are Inflammasome Components that Are Mediated by P2Y2R Activation in Breast Cancer Cells. (PMID:32397236)
• ASC-1 transporter-dependent amino acid uptake is required for the efficient thermogenic response of human adipocytes to adrenergic stimulation. (PMID:34197627)
• Impaired Adipocyte SLC7A10 Promotes Lipid Storage in Association With Insulin Resistance and Altered BCAA Metabolism. (PMID:36916878)
• Dual Role of Dysfunctional Asc-1 Transporter in Distinct Human Pathologies, Human Startle Disease, and Developmental Delay. (PMID:37903619)

Cross-species orthologs

17 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc7a10a	ENSDARG00000008100
danio_rerio	slc7a10b	ENSDARG00000051730
mus_musculus	Slc7a10	ENSMUSG00000030495
rattus_norvegicus	Slc7a10	ENSRNOG00000010938
drosophila_melanogaster	mnd	FBGN0002778
drosophila_melanogaster	CG7255	FBGN0036493
drosophila_melanogaster	CG5535	FBGN0036764
drosophila_melanogaster	CG13248	FBGN0036984
drosophila_melanogaster	slif	FBGN0037203
drosophila_melanogaster	CG1607	FBGN0039844
caenorhabditis_elegans		WBGENE00000002
caenorhabditis_elegans		WBGENE00000003
caenorhabditis_elegans		WBGENE00000005
caenorhabditis_elegans	aat-9	WBGENE00000010
caenorhabditis_elegans		WBGENE00015197
caenorhabditis_elegans		WBGENE00016806
caenorhabditis_elegans		WBGENE00017747

Paralogs (12): SLC7A2 (ENSG00000003989), SLC7A14 (ENSG00000013293), SLC7A9 (ENSG00000021488), SLC7A8 (ENSG00000092068), SLC7A4 (ENSG00000099960), SLC7A6 (ENSG00000103064), SLC7A5 (ENSG00000103257), SLC7A1 (ENSG00000139514), SLC7A11 (ENSG00000151012), SLC7A7 (ENSG00000155465), SLC7A13 (ENSG00000164893), SLC7A3 (ENSG00000165349)

Protein

Protein identifiers

Asc-type amino acid transporter 1 — Q9NS82 (reviewed: Q9NS82)

Alternative names: Solute carrier family 7 member 10

All UniProt accessions (3): Q9NS82, K7EK24, K7ENB6

UniProt curated annotations — full annotation on UniProt →

Function. Associates with SLC3A2/4F2hc to form a functional heterodimeric complex that translocates small neutral L- and D-amino acids across the plasma membrane. Preferentially mediates exchange transport, but can also operate via facilitated diffusion. Acts as a major transporter for glycine, L- and D-serine in the central nervous system. At the spinal cord and brainstem regulates glycine metabolism and glycinergic inhibitory neurotransmission by providing for glycine de novo synthesis from L-serine and glycine recycling from astrocytes to glycinergic motor neurons. At Schaffer collateral-CA1 synapses mediates D-serine and glycine release that modulates post-synaptic activation of NMDA receptors and excitatory glutamatergic transmission. May regulate D-serine release from mesenchymal progenitors located in developing subcutaneous adipose tissue, favoring white adipocyte over thermogenic beige adipocyte lineage commitment.

Subunit / interactions. Disulfide-linked heterodimer with the amino acid transport protein SLC3A2/4F2hc.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in brain, heart, kidney, liver, lung, pancreas, placenta, and skeletal muscle.

Similarity. Belongs to the amino acid-polyamine-organocation (APC) superfamily.

RefSeq proteins (1): NP_062823* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002293	AA/rel_permease1	Family
IPR050598	AminoAcid_Transporter	Family

Pfam: PF13520

Catalyzed reactions (Rhea), 12 shown:

• D-serine(in) = D-serine(out) (RHEA:29455)
• L-alanine(in) + glycine(out) = L-alanine(out) + glycine(in) (RHEA:74019)
• L-serine(out) + L-alanine(in) = L-serine(in) + L-alanine(out) (RHEA:74023)
• L-threonine(out) + L-alanine(in) = L-threonine(in) + L-alanine(out) (RHEA:74027)
• L-cysteine(out) + L-alanine(in) = L-cysteine(in) + L-alanine(out) (RHEA:74031)
• D-serine(out) + L-alanine(in) = D-serine(in) + L-alanine(out) (RHEA:74035)
• D-alanine(out) + L-alanine(in) = D-alanine(in) + L-alanine(out) (RHEA:74039)
• L-methionine(out) + L-alanine(in) = L-methionine(in) + L-alanine(out) (RHEA:74043)
• L-valine(out) + L-alanine(in) = L-valine(in) + L-alanine(out) (RHEA:74047)
• D-threonine(out) + L-alanine(in) = D-threonine(in) + L-alanine(out) (RHEA:74051)
• D-cysteine(out) + L-alanine(in) = D-cysteine(in) + L-alanine(out) (RHEA:74055)
• beta-alanine(out) + L-alanine(in) = beta-alanine(in) + L-alanine(out) (RHEA:74059)

UniProt features (46 total): helix 23, transmembrane region 9, turn 4, strand 4, region of interest 2, sequence variant 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8WNS	ELECTRON MICROSCOPY	3.42
8WNT	ELECTRON MICROSCOPY	3.42
8WNY	ELECTRON MICROSCOPY	3.5
8QEY	ELECTRON MICROSCOPY	4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS82-F1	83.79	0.50

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-210991	Basigin interactions
R-HSA-352230	Amino acid transport across the plasma membrane
R-HSA-109582	Hemostasis
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-382551	Transport of small molecules
R-HSA-425393
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 128 (showing top): GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, LFA1_Q6, GOBP_REGULATION_OF_BROWN_FAT_CELL_DIFFERENTIATION, AP2_Q3, GOBP_AMINO_ACID_TRANSMEMBRANE_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_ORGANIC_ACID_TRANSPORT, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, GOBP_AMINO_ACID_TRANSPORT, GOBP_BROWN_FAT_CELL_DIFFERENTIATION, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_ORGANIC_ANION_TRANSPORT, GGCKCATGS_UNKNOWN

GO Biological Process (10): amino acid transport (GO:0006865), neutral amino acid transport (GO:0015804), glycine transport (GO:0015816), D-alanine transmembrane transport (GO:0042941), D-serine transmembrane transport (GO:0042942), positive regulation of synaptic transmission, glycinergic (GO:0060094), negative regulation of brown fat cell differentiation (GO:1903444), L-serine transport (GO:0015825), transmembrane transport (GO:0055085), L-alpha-amino acid transmembrane transport (GO:1902475)

GO Molecular Function (6): neutral L-amino acid transmembrane transporter activity (GO:0015175), L-amino acid transmembrane transporter activity (GO:0015179), L-serine transmembrane transporter activity (GO:0015194), protein binding (GO:0005515), obsolete organic cation transmembrane transporter activity (GO:0015101), transmembrane transporter activity (GO:0022857)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Cell surface interactions at the vascular wall	1
SLC-mediated transport of amino acids	1
Hemostasis	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
amino acid transmembrane transport	3
carboxylic acid transmembrane transport	3
transport	2
neutral amino acid transport	2
D-amino acid transport	2
serine transport	2
L-amino acid transport	2
amino acid transmembrane transporter activity	2
amino acid transport	1
carboxylic acid transport	1
nitrogen compound transport	1
alanine transport	1
positive regulation of synaptic transmission	1
synaptic transmission, glycinergic	1
regulation of synaptic transmission, glycinergic	1
negative regulation of fat cell differentiation	1
brown fat cell differentiation	1
regulation of brown fat cell differentiation	1
cellular process	1
carboxylic acid transmembrane transporter activity	1
L-alpha-amino acid transmembrane transport	1
L-amino acid transmembrane transporter activity	1
L-serine transport	1
binding	1
transporter activity	1
transmembrane transport	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

880 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC7A10	SLC3A2	P08195	974
SLC7A10	SLC1A4	P43007	612
SLC7A10	SLC1A5	Q15758	528
SLC7A10	OVCH2	Q7RTZ1	521
SLC7A10	SLC3A1	Q07837	512
SLC7A10	SLC36A2	Q495M3	487
SLC7A10	SLC1A1	P43005	447
SLC7A10	C8orf82	Q6P1X6	436
SLC7A10	SLC6A9	P48067	423
SLC7A10	SLC6A5	Q9Y345	411
SLC7A10	SRR	Q9GZT4	404
SLC7A10	TMEM26	Q6ZUK4	403
SLC7A10	SLC38A2	Q96QD8	391
SLC7A10	SLC38A1	Q9H2H9	390
SLC7A10	P2RX5	Q93086	378

IntAct

8 interactions, top by confidence:

A	B	Type	Score
APPBP2	SLC7A10	psi-mi:“MI:0915”(physical association)	0.560
CREB3	SLC7A10	psi-mi:“MI:0915”(physical association)	0.370
SLC7A10	CFTR	psi-mi:“MI:0915”(physical association)	0.370
CFTR	SLC7A10	psi-mi:“MI:0915”(physical association)	0.370
SLC7A10	MYO1C	psi-mi:“MI:0914”(association)	0.350
SLC7A10	APPBP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (7): SLC7A10 (Two-hybrid), SLC7A10 (PCA), CA12 (Affinity Capture-MS), CORO1C (Affinity Capture-MS), MYO1C (Affinity Capture-MS), SLC3A2 (Affinity Capture-MS), SLC7A8 (Affinity Capture-MS)

ESM2 similar proteins: A0A6P3HVI0, A0FKN5, A2VDL4, O04289, O14520, O35874, O43511, O70247, O70531, P24942, P33124, P40879, P43003, P43007, P46411, P50443, P53392, P56564, P63115, P63116, P92943, Q495M3, Q5BKR2, Q5R6B8, Q5U4D8, Q60414, Q62273, Q65AC2, Q69DJ1, Q7T2C4, Q86UD5, Q8BHK3, Q8CIW6, Q8K415, Q8WWT9, Q91WC3, Q924C9, Q9BEG8, Q9BXS9, Q9GJY3

Diamond homologs: A1L3M3, D3ZMM8, O34739, P63115, P63116, P82251, P82252, Q01650, Q22397, Q28I80, Q59I64, Q5RAE3, Q5RAG7, Q5RKI7, Q63016, Q7YQK4, Q8BGK6, Q8MH63, Q8TCU3, Q91WN3, Q92536, Q9GIP4, Q9N1Q4, Q9N1R6, Q9NS82, Q9QXA6, Q9QXW9, Q9R0S5, Q9UHI5, Q9UM01, Q9UPY5, Q9WTR6, Q9WVR6, Q9Z127, Q9Z1K8, Q8VIE6, A0JNI9, A8I499, B0UYF2, B3TP03

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	11
Benign	13

Top pathogenic / likely-pathogenic (0)

SpliceAI

1782 predictions. Top by Δscore:

Variant	Effect	Δscore
19:33209483:CAC:C	acceptor_gain	1.0000
19:33209484:ACCT:A	acceptor_loss	1.0000
19:33209485:CCTGG:C	acceptor_loss	1.0000
19:33209486:C:A	acceptor_loss	1.0000
19:33209486:C:CC	acceptor_gain	1.0000
19:33209487:T:C	acceptor_loss	1.0000
19:33210461:CCTCA:C	donor_loss	1.0000
19:33210462:CTCA:C	donor_loss	1.0000
19:33210464:CA:C	donor_loss	1.0000
19:33210465:A:AC	donor_gain	1.0000
19:33210465:A:AT	donor_loss	1.0000
19:33210466:C:CC	donor_gain	1.0000
19:33210466:C:CT	donor_loss	1.0000
19:33210542:G:GC	acceptor_gain	1.0000
19:33210546:T:TC	acceptor_gain	1.0000
19:33210617:C:CC	acceptor_gain	1.0000
19:33211220:GTCAC:G	donor_loss	1.0000
19:33211221:TCA:T	donor_loss	1.0000
19:33211222:CA:C	donor_loss	1.0000
19:33211223:AC:A	donor_loss	1.0000
19:33211224:C:G	donor_loss	1.0000
19:33211327:GTCT:G	acceptor_loss	1.0000
19:33211328:TC:T	acceptor_loss	1.0000
19:33211329:C:CC	acceptor_gain	1.0000
19:33211410:TCA:T	donor_loss	1.0000
19:33211411:CAC:C	donor_loss	1.0000
19:33211412:A:AC	donor_gain	1.0000
19:33211412:A:C	donor_loss	1.0000
19:33211413:C:CC	donor_gain	1.0000
19:33211413:C:G	donor_loss	1.0000

AlphaMissense

3365 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:33211418:G:T	A303D	0.999
19:33215890:A:G	W79R	0.999
19:33215890:A:T	W79R	0.999
19:33211439:A:G	L296P	0.998
19:33211469:G:T	A286D	0.998
19:33211474:G:C	N284K	0.998
19:33211474:G:T	N284K	0.998
19:33215928:A:G	L66P	0.998
19:33215948:G:C	F59L	0.998
19:33215948:G:T	F59L	0.998
19:33215950:A:G	F59L	0.998
19:33211467:A:C	Y287D	0.997
19:33212351:G:C	F243L	0.997
19:33212351:G:T	F243L	0.997
19:33212353:A:G	F243L	0.997
19:33211321:C:T	G307E	0.996
19:33211467:A:G	Y287H	0.996
19:33211470:C:G	A286P	0.996
19:33212535:C:G	G205R	0.996
19:33215877:C:T	G83E	0.996
19:33215878:C:G	G83R	0.996
19:33215878:C:T	G83R	0.996
19:33215888:C:A	W79C	0.996
19:33215888:C:G	W79C	0.996
19:33215931:A:T	V65D	0.996
19:33215940:G:T	P62H	0.996
19:33212534:C:T	G205D	0.995
19:33215949:A:C	F59C	0.995
19:33211322:C:G	G307R	0.994
19:33211322:C:T	G307R	0.994

dbSNP variants (sampled 300 via entrez): RS1000020126 (19:33220022 C>T), RS1000269239 (19:33214788 A>G), RS1000269834 (19:33221801 A>C), RS1000307483 (19:33225872 C>T), RS1000473195 (19:33209628 G>A), RS1000512302 (19:33216329 C>T), RS1000636416 (19:33213102 C>G,T), RS1000777214 (19:33218090 G>A,C), RS1001005433 (19:33216027 G>A), RS1001192316 (19:33227390 C>G), RS1001323765 (19:33223131 A>T), RS1001447432 (19:33208267 A>T), RS1001476796 (19:33208483 C>A), RS1001608747 (19:33213956 C>T), RS1001807349 (19:33212816 T>C)

Disease associations

OMIM: gene MIM:607959 | disease phenotypes: MIM:601626

GenCC curated gene-disease

Mondo (1): acute myeloid leukemia (MONDO:0018874)

Orphanet (1): Acute myeloid leukemia (Orphanet:519)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

23 associations (top):

Study	Trait	p-value
GCST001523_28	Visceral adipose tissue adjusted for BMI	1.000000e-06
GCST001524_24	Visceral adipose tissue/subcutaneous adipose tissue ratio	5.000000e-06
GCST005038_53	Allergic disease (asthma, hay fever or eczema)	6.000000e-18
GCST005976_24	White blood cell count (basophil)	3.000000e-13
GCST005996_8	Red blood cell count	5.000000e-08
GCST006409_11	Allergic rhinitis	6.000000e-13
GCST007563_5	Allergic disease (asthma, hay fever or eczema)	3.000000e-08
GCST007564_37	Asthma or allergic disease (pleiotropy)	3.000000e-10
GCST007798_110	Asthma	1.000000e-27
GCST007799_10	Asthma (adult onset)	3.000000e-18
GCST007800_45	Asthma (childhood onset)	3.000000e-29
GCST007941_37	Medication use (adrenergics, inhalants)	6.000000e-18
GCST007942_6	Medication use (glucocorticoids)	2.000000e-09
GCST008916_25	Asthma	1.000000e-21
GCST009597_228	Multiple sclerosis	4.000000e-06
GCST009720_72	Asthma	3.000000e-23
GCST009798_7	Asthma	1.000000e-23
GCST010042_140	Asthma	2.000000e-29
GCST010043_72	Asthma	9.000000e-28
GCST010244_404	Triglyceride levels	3.000000e-10
GCST012017_4	Mastocytosis (KIT D816V positive)	1.000000e-15
GCST90002381_339	Eosinophil count	8.000000e-15
GCST90014325_71	Asthma	4.000000e-21

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004767	visceral:subcutaneous adipose tissue ratio
EFO:0005090	basophil count
EFO:0004305	erythrocyte count
EFO:1002011	adult onset asthma
EFO:0009941	Inhalant adrenergic use measurement
EFO:0009942	Glucocorticoid use measurement
EFO:0004530	triglyceride measurement
EFO:0004842	eosinophil count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015470	Leukemia, Myeloid, Acute	C04.557.337.539.275; C15.378.508.539.275

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC7 family

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	9
entinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Diethylhexyl Phthalate	decreases expression, increases expression	2
dicrotophos	increases expression	1
propionaldehyde	increases expression	1
trichostatin A	increases expression	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	affects expression	1
Aldehydes	increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects expression	1
Copper	affects cotreatment, decreases expression	1
Triclosan	increases expression	1
Zidovudine	increases expression, decreases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4UH	HuH7-SLC7A10-KO-c6	Cancer cell line	Male
CVCL_D4UI	HuH7-SLC7A10-KO-c7	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00199147	PHASE4	UNKNOWN	Efficacy of G-CSF-Priming in Elderly AML Patients
NCT00304447	PHASE4	COMPLETED	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
NCT00464217	PHASE4	COMPLETED	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00487448	PHASE4	COMPLETED	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
NCT00488709	PHASE4	COMPLETED	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01041040	PHASE4	COMPLETED	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
NCT01198054	PHASE4	TERMINATED	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
NCT01200355	PHASE4	COMPLETED	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
NCT01347996	PHASE4	COMPLETED	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
NCT01587430	PHASE4	UNKNOWN	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
NCT01819792	PHASE4	COMPLETED	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia
NCT02024308	PHASE4	UNKNOWN	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02027064	PHASE4	UNKNOWN	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
NCT02277847	PHASE4	UNKNOWN	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT02926586	PHASE4	COMPLETED	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT02933333	PHASE4	UNKNOWN	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
NCT03026842	PHASE4	UNKNOWN	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
NCT03150134	PHASE4	UNKNOWN	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
NCT05144243	PHASE4	ACTIVE_NOT_RECRUITING	Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT06370000	PHASE4	RECRUITING	Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06571825	PHASE4	RECRUITING	RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07044687	PHASE4	RECRUITING	Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07486713	PHASE4	RECRUITING	Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07561892	PHASE4	RECRUITING	Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT00000589	PHASE3	COMPLETED	Trial to Reduce Alloimmunization to Platelets (TRAP)
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00093990	PHASE3	COMPLETED	Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00125606	PHASE3	TERMINATED	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00136084	PHASE3	COMPLETED	Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00146120	PHASE3	COMPLETED	Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
NCT00150878	PHASE3	TERMINATED	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
NCT00151255	PHASE3	COMPLETED	All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00152139	PHASE3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152594	PHASE3	TERMINATED	Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
NCT00186966	PHASE3	COMPLETED	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00226512	PHASE3	WITHDRAWN	To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
NCT00260832	PHASE3	COMPLETED	Trial of Decitabine in Patients With Acute Myeloid Leukemia